The rights to a drug which could fight a type of high blood pressure have been won by Pfizer, the firm has announced.
Terguride is an experimental drug to treat pulmonary arterial hypertension currently being tested by the Swiss firm Ergonex.
Pfizer struck a deal with the firm for the rights to terguride worldwide with the exception of Japan, and will cover the costs of completing mid-stage trials.
Japan has already approved the drug to treat the hormone disorder hyperprolactinemia, which can cause infertility.
Pulmonary arterial hypertension is a progressive disease with no cure that affects lung arteries and the right side of the heart.
Subject to eventual approval, Ergonex will receive royalties on sales.
As a drug treating a rare disease, the EU and US offer terguride “orphan drug status”, which will mean tax incentives and market exclusivity for Pfizer.
Copyright Press Association 2010